Secondary analysis of the phase III PANTHER trial (1566 women on adjuvant chemotherapy for early high-risk breast cancer): clinician CTCAE grades agreed poorly with patient-reported symptoms (kappa 0.07–0.34), mostly underrating them, especially fatigue and pain.
Secondary analysisn = 1,566
Filis et al. Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial